Markers of neuroprotection of combined EPA and DHA provided by fish oil are higher than those of EPA (Nannochloropsis) and DHA (Schizochytrium) from microalgae oils in Wistar rats

Paula A. Lopes¹†, Narcisa M. Bandarra²,³†, Susana V. Martins¹, Joana Martinho¹, Cristina M. Alfaia¹, Marta S. Madeira¹, Carlos Cardoso²,³, Cláudia Afonso²,³, Maria C. Paulo⁴, Rui M. A. Pinto⁵,⁶, José L. Guil-Guerrero⁷ and José A. M. Prates¹†

Abstract

Background: To overcome the current overexploitation of fish rich in n-3 long chain polyunsaturated fatty acids (LCPUFA), microalgae have become a promising marine lipid source. The purpose of this study was to assess eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3), isolated or combined from distinct marine origins, on the promotion of neuroprotective effects.

Methods: The experiment lasted for 10 weeks and involved 32 Wistar rats, divided into 4 diets (n = 8): a diet rich in milk fat was taken as control (Milk Fat) and compared to n-3 LCPUFA enriched diets, either in EPA + DHA form through fish oil (Fish Oil), or EPA through Nannochloropsis oil (Nanno), or DHA through Schizochytrium oil (Schyzo), while maintaining Milk Fat incorporation.

Results: Plasma lipid profile and dopamine levels were more beneficial in Fish Oil diet. In addition, n-3 LCPUFA incorporation was found increased in liver and erythrocytes from Fish Oil fed rats, suggesting that fish oil is a better dietary source for fatty acids deposition in the organism than microalgae. The Forced Swimming Test revealed a positive behavioural action of EPA + DHA, in opposition to Milk Fat and Nanno diets, which had higher immobile times. mRNA levels of serotonin receptors, HT1A and HT2A along with CREB, the transmission factor for learning and memory, were higher in the hippocampus of rats fed n-3 LCPUFA diets comparative to Milk Fat.

Conclusion: Taken together, the combination of EPA and DHA from fish oil can counteract the undesirable health effects of saturated fat based diets and benefit, in the long run, neurological function.

Keywords: Fish oil, Microalgae, Fatty acid composition, Forced swimming test, Transcriptional profile
Background

Aging represents the accumulation of changes over time that are associated with or responsible for increased susceptibility to most diseases and death [1]. The European population is getting older and until 2030 the number of seniors aged over 70 is predicted to increase 40%, as will age-related neurodegenerative diseases [2, 3].

The improvement of health of the elderly population through a diet rich in essential nutrients may mitigate the effects of ageing. Precisely, essential nutrients such as n-3 long-chain polyunsaturated fatty acids (n-3 LCPUFA, > 18 C), particularly eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3), are associated to a prophylactic role in certain age-related diseases with particular emphasis to some of the effects of certain degenerative diseases of the nervous system. These FA have a protective role on regulating brain development and neurotransmitter functioning and are recognised as the most beneficial FA in retarding neurological pathologies, such as Alzheimer’s, Parkinson’s and Huntington’s diseases, multiple sclerosis, schizophrenia, cognitive decline and brain ageing, major depression, acute stress and anxiety like behaviours [4–7]. Their deficiency leads to impaired neuronal function, affecting neurotransmission action [8, 9]. Accordingly, the international nutritional guidelines have recommended the need to increase EPA and DHA intake.

In the human body, DHA is synthesised in limited amounts and, therefore, must be obtained through the diet [10]. Fatty fish is the best source of n-3 LCPUFA [11]. However, due to the excessive and sometimes poorly regulated fishery exploitation, the depletion of worldwide fish stocks is aggravating their sustainability. Thus, search for alternative sources of n-3 LCPUFA to increase their availability and the consumption of these healthy FA is a major demand. Microalgae are a viable option for n-3 LCPUFA production because they do not require arable land for their growth and can operate as biofactories using only sunlight energy, thereby having the ability to accumulate high levels of FA under adverse environmental conditions [12]. In fact, new improvements on microalgae production have been made concerning growth optimization requirements, able to produce highly pure EPA and DHA oils [13] containing up to 30–40% of a target FA [14]. Some microalgae oils have also demonstrated safety nutritional profiles with no trace of toxicity, because they are produced under controlled conditions, thus being approved for consumption by the Food and Drug Administration.

Despite the body of evidence on n-3 LCPUFA positive effects on retarding and treating the neurologic conditions stated above [15, 16], a key question remains to be answered [17, 18]: are the benefits ascribed to EPA and DHA individual action or a result from the combination of both fatty acids (EPA + DHA)?

In this study, the impact of microalgae oils rich in EPA and DHA, as alternative marine lipid sources to fish oils was assessed on the neurological function of Wistar rats. We hypothesised that blue biotechnology can efficiently provide n-3 LCPUFA to counteract the undesirable health effects of saturated fat based diets by means of improving the biochemical profile, changing FA composition of key tissues, preventing inflammatory processes, enhancing neurological function, and modifying rat’s behaviour. To establish the effects of EPA and DHA, isolated or combined, on the promotion of neuroprotective effects, fish oil was used for comparative purposes.

Methods

Experimental diets

Diets were manufactured by the Experimental Diets Unit from the University of Almería, Spain. The proximate chemical composition of the diets was determined according to AOAC [19], and FA composition was assessed as described by Bandarra et al. [20]. All diets were based on the standard AIN-93 M formulation for rodents with modified lipid fractions, as follows: milk fat diet (Milk Fat group), a negative control with 20% of fat (12% from milk and 8% from soybean oil); milk fat diet plus cod liver oil (Fish Oil group), a positive control with 20% of fat (12% from milk, 4% from soybean oil and 4% from cod liver oil which is rich in EPA and DHA); milk fat diet plus Nannochloropsis microalga oil (Nanno group) with 20% of fat (12.5% from milk fat, 5.9% from soybean oil and 2.4% from Nanno oil which is rich in EPA); milk fat diet plus Schizochytrium microalga oil (Schyzo group) with 20% of fat (12.2% from milk fat, 6.5% from soybean oil and 1.8% from Schyzo oil which is rich in DHA) (Table 1). Nannochloropsis was purchased at Monzón BIOTECH, S.L. (Barcelona, Spain) and Schizochytrium was produced by Instituto Português do Mar e da Atmosfera (IPMA, Lisboa, Portugal), according to conditions outlined in previous studies [21].

Animals and sample collection

A total of thirty-two male Wistar rats (Harlan Interfera Iberica SL, Barcelona, Spain), aged 28 d, were housed individually under a 12 h light-12 h dark cycle and at a temperature of 22–25 °C. After an adaptation period of 1 week to minimise stress and stabilise all metabolic conditions, rats were assigned to four body weight-matched groups with eight animals each: Milk Fat, Fish Oil, Nanno and Schyzo. Body weight and feed intake were recorded twice a week. Faeces were collected and stored at −80 °C in vacuum bags for further FA analysis. At the end of 10 weeks, rats were fasted for 12 h and killed by decapitation, under light isoflurane anaesthesia. The trunk blood was collected in lithium heparin tubes and was left to stand for 30 min. Plasma was obtained
after centrifugation at 1500 g for 10 min. Erythrocytes were obtained after washing the pellet twice with 0.9% sodium chloride and centrifuging at 1500 g for 15 min and the correspondent aliquots were flash-frozen in liquid N₂ and stored at -80 °C, for further analysis. Liver, brain and hippocampus were removed, weighed and stored at -80 °C for FA determination. Samples for gene expression analysis were collected from the hippocampus, rinsed with sterile RNAse-free cold saline solution, cut into small pieces (thickness of ~0.3 cm), stabilised in RNA Later® solution (Qiagen, Hilden, Germany) and stored at -80 °C.

**Plasma biochemical assays**

The plasma concentrations of total cholesterol, HDL-cholesterol, LDL-cholesterol, triacylglycerols (TAG), glucose, creatinine, urea, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) and gamma glutamyl transferase (γ-GT) were determined using standard diagnostic test kits obtained from Roche Diagnostics (Mannheim, Germany) in the Modular Hitachi Analytical System (Roche Diagnostics). The concentrations of VLDL-cholesterol and total lipids were calculated according to the Friedewald et al. [22] and Covaci et al. [23] formulas, respectively.

TNF-α and IL-6 were measured simultaneously, in duplicate, using Millipore’s MILLIPLEX rat cytokine panel (Millipore, Billerica, MA, USA). The assays were conducted according to the manufacturer’s instructions. The plate was run on a Luminex 200 Instrument using Bio-Plex Manager 4.1 standard software (Bio-Rad Laboratories, Hercules, CA, USA). Raw fluorescence data were analysed by software using a 5-parameter logistic method. The minimum detection concentrations were 2.4 pg/ml and 73.2 pg/ml for TNF-α and IL-6, respectively. The intra- and inter-assay precision of the cytokine panel were 2.3–3.6% and 11.3–14.3%, respectively.

**Fatty acid composition in faeces, liver, erythrocytes and brain**

After lipid extraction by the Bligh and Dyer method [24], fatty acid methyl esters (FAME) were determined in the extracted lipids from faeces, liver, erythrocytes and brain by acid-catalysed transesterification using the methodology described by Bandarra et al. [25]. Samples were injected into a Varian Star 3800 CP gas chromatograph (Walnut Creek, CA, USA), equipped with an auto sampler with a flame ionisation detector (FID) at 250 °C. FAME were identified by comparing their retention times with those of standards (PUFA-3, Menhaden oil, Table 1

| Ingredients (g/100 g) | Milk Fat | Fish Oil | Nanno | Schyzo |
|-----------------------|----------|----------|-------|--------|
| Crude protein (%)     | 12.3     | 12.1     | 14.7  | 12.6   |
| Crude fat (%)         | 19.2     | 20.2     | 17.0  | 21.6   |
| Moisture (%)          | 5.60     | 5.60     | 5.60  | 6.00   |
| Crude ash (%)         | 3.57     | 3.50     | 3.82  | 3.60   |
| Carbohydrates (%)     | 55.6     | 54.8     | 55.0  | 52.9   |
| Total FAME (mg/g)     | 220      | 202      | 236   | 185    |
| Energy (kcal/100 g)   | 444      | 449      | 432   | 456    |

| Fatty acid profile (%) | 14:0 | 16:0 | 18:0 | 18:1 n-9 | 18:2 n-6 | 18:3 n-3 | 18:4 n-3 | 20:4 n-6 | 20:5 n-3 | 22:6 n-3 |
|-----------------------|------|------|------|-----------|-----------|----------|----------|----------|----------|----------|
| 14:0                  | 9.81 | 8.5  | 6.95 | 20.3      | 21.2      | 2.56     | 1.90     | 0.086    | ND       | ND       |
| 16:0                  | 28.5 | 28.8 | 6.95 | 19.1      | 12.3      | 1.59     | 0.410    | 0.138    | 1.15     | 1.90     |
| 18:0                  | 69.5 | 68.7 | 19.1 | 18.0      | 15.7      | 1.88     | 0.410    | 0.138    | 1.15     | 1.90     |
| 18:1 n-9              | 20.3 | 19.1 | 18.0 | 17.0      | 16.3      | 2.04     | 0.189    | 0.087    | 0.10     | 0.10     |
| 18:2 n-6              | 21.2 | 12.3 | 15.7 | 16.3      | 21.2      | 2.04     | 0.189    | 0.087    | 0.10     | 0.10     |
| 18:3 n-3              | 2.56 | 1.59 | 1.88 | 2.04      | 2.04      | 1.88     | 0.189    | 0.087    | 0.10     | 0.10     |
| Partial sums and ratios |      |      |      |           |           |          |          |          |          |          |
| Total SFA (%)         | 51.1 | 52.9 | 51.2 | 52.1      | 52.1      | 21.4     | 12.7     | 16.4     | 17.8     | 17.8     |
| Total MUFA (%)        | 22.0 | 26.6 | 23.8 | 20.4      | 20.4      | 2.75     | 4.64     | 5.23     | 5.72     | 5.72     |
| Total PUFA (%)        | 24.3 | 17.8 | 21.9 | 23.7      | 23.7      | 21.0     | 12.7     | 16.4     | 17.8     | 17.8     |
| Total n-3 (%)         | 2.75 | 4.64 | 5.23 | 5.72      | 5.72      | 1.29     | 0.366    | 0.320    | 0.321    | 0.321    |

**TBHQ** tertiary butyl hydroquinone, ND not detected
and PUFA-1, Marine Source from Supelco Analytical, Sigma-Aldrich, St. Louis, MO, USA). The quantification of total FA was based on the internal standard technique, using the heicicosanoic acid (21:0) (Sigma-Aldrich). Results for each FA were expressed as a percentage of the sum of detected FA (% total FA).

Lipid class analysis in brain

The main lipid classes were separated by analytical thin-layer chromatography (TLC) in plates coated with 0.25 mm silica gel G and developed with a mixture of chloroform:methanol:water (56:41:3 by volume), based on Bandarra et al. [25]. The developed plates were sprayed with 10% of phosphomolybdic acid in ethanol (w/v). The identification of lipid classes (polar and non-polar) was performed by comparison with standards (Sigma Chemical Co., St. Louis, MO, USA) and the quantification using a scanner and Quantity One 1-D Analysis software (version 4.5.2, Bio-Rad) [25].

Behavioural analysis: Forced swimming test

The behavioural effects of n-3 LCPUFA were tested one week prior to euthanasia using the blinded Forced Swimming Test (FST), according to Porsolt et al. [26] with slight modifications. The identification of rats was ensured by a code in order to avoid bias. Each rat was put individually into vertical cylinders (60 cm height and 20 cm diameter) containing water at 25 °C (± 2 °C) with 30 cm deep for a 15 min pre-test. The cylinders were made of transparent Plexiglas as this material is able to withstand the frequent movement of the tanks and accidents better than glass. Water volume prevented the animal from escaping or touching the bottom of the cylinder. Behavioural tests were done individually, one at a time, to prevent copying and avoid bias. The room was under control to guarantee that noises, light changing or reflexes would not affect rat’s behaviour. At the end of the pre-test, the animal was taken from the water, dried with a towel to prevent hypothermia and then put back into its cage, so it could rapidly resettle to its normal conditions. The water was changed after each experiment to remove urine, faeces and odour clues left by the previous rat and thus, to avoid interferences on the next rat. 24 h later, the rat was exposed to the same aforementioned experimental conditions for a 5 min FST. This final test was recorded by a conventional video camera positioned in front of the Plexiglas cylinder. Behavioural times were calculated with proper software [27] (Ethowatcher®) and classified from most active to least active, as climbing (active upward movement), swimming (active lateral movement), floating (passive fluctuating movement) and immobile (absence of movement).

Determination of serotonin and catecholamines

Plasma 5-hydroxytryptamine (5-HT, serotonin) and catecholamines were determined by high-performance liquid chromatography – electrochemical detection method (HPLC-ECD).

Serotonin was determined using a ClinRep kit for “serotonin in plasma/serum” (Recipe Chemicals + Instruments GmbH, Munich, Germany). Briefly, 200 μl of plasma containing N-methylserotonin as an internal standard (10 μl) was precipitated to remove proteins and lipids. The supernatant was separated on a Shimadzu series 10 HPLC system by a reversed-phase column and using an isocratic mobile phase (ClinRep, ref.: 6710) equipped with a Shimadzu series 6 electrochemical detector. The conditions for obtaining the chromatograms were as follows: a) temperature: 30 °C; b) detector: potential - 0.45 V; c) flow: 1.0 ml/min. Data obtained from the HPLC system were treated using software suitable for this type of assays (Shimadzu class 10-A software). Quality control of the system was accomplished by running ClinRep controls in two levels. The day-to-day CV was 5.4% and 5.3%, respectively. The lower limit of quantitation (LLOQ) was 1 μg/l. Catecholamines were determined using a Bio-Rad kit for “Plasma catecholamines by HPLC” (Bio-Rad, Madrid, Spain). Briefly, 50 μl of plasma containing dihydroxybenzylamine as an internal standard (5 μl) was treated with alumina (extraction phase). HPLC analysis of the supernatant was performed with an analytical cation exchange column specific for catecholamines PCAT (Bio-Rad, ref.: 195–6079) and an isocratic mobile phase purchased from Bio-Rad (ref: 195–6056). Catecholamines determinations were performed on a Shimadzu series 10 HPLC system equipped with a Shimadzu series 6 electrochemical detector. The conditions for obtaining the chromatograms were as follows: a) temperature: 30 °C; b) detector: potential - 0.50 V; c) flow: 1.1 ml/min. Data obtained from the HPLC system were treated using software suitable for this type of assays (Shimadzu class 10-A software). In each series of determinations, control samples (Lyphochek, Bio-Rad, ref. 530) were analysed in order to monitor the quality of each of the assays performed. The day-to-day CV was 4.9%. The lower limit of quantitation (LLOQ) was 25 pg/ml.

Hippocampus RNA extraction and cDNA synthesis

Total RNA was extracted from hippocampus using the RNeasy Lipid Tissue Mini Kit (Qiagen, Hilden, Germany). To exclude possible existing genomic DNA, on-column DNase digestion with the RNase-Free DNase set (Qiagen) was performed. All procedures were based on the manufacturer’s protocol. RNA quality and concentration were determined by spectrophotometry at A260 and by the A260/A280 ratio using a NanoDrop®
Real time quantitative PCR (RT-qPCR)

mRNA expression levels were quantified using the SYBR green technology and MicroAmp Optical 96-well plates in a StepOnePlus thermocycler at standard cycling conditions (Applied Biosystems). Gene specific intron-spanning primers were designed using Primer Express® Software v.3.0 (Applied Biosystems) based on homologous sequences (www.ncbi.nlm.nih.gov). Specific sense and antisense primers used to amplify cDNA were purchased from NZYTech (Lisbon, Portugal). The specific primers were: HT1A (5′-GATCTTCGTCACTTGGCTGCTA-3′ and 5′-AGCGCCGAAGTGGAGTGA-3′); HT2A (5′-CACACAGGCCGTCACT-3′ and 5′-CACACAGCCTGCTCAACT-3′); BDNF (5′-AGGGATCCACACTGCCACTG-3′ and 5′-GAAATCTCTGCTGCTGGCAG-3′); CREB (5′-CCTCCCCAGCAGCCTCTACA-3′ and 5′-TCAGCCTGGCCACACTCTTGTC-3′); TNF-α (5′-TCTTCTCATTCTGCTGCTTG-3′ and 5′-GCTGGCAGCATGGAATCGAT-3′); IL-6 (5′-GGATACCAACCCACACACAGACCC-3′ and 5′-AGTGCACTCAGCGCTGCTCTACA-3′); glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (5′-CAGTGGCAGCCTCGTCTCAT-3′ and 5′-CACAAGAGGGCAGCCTCGTCTCAT-3′); and ribosomal protein L27 (RPL27) (5′-GGCATGGAAGAGAACAGTC-3′ and 5′-GCTGGGCTCTGGAACACACCTCT-3′). PCR efficiency was calculated for each amplicon using the StepOnePlus PCR System software, by amplifying 5-fold serial dilutions of pooled cDNA and running in triplicate. All primer sets were required to exhibit similar amplification efficiencies. The primer specificity and formation of primer-dimers were checked by melt curve analysis. A set of four candidate housekeeping genes was evaluated using geNorm and NormFinder, as described by Vandesompele et al. [28] and Andersen et al. [29], respectively. GADPH and RPL27 genes were selected as the most stable pair of internal controls for normalization. All analyses were performed in duplicate, and the relative amounts for each target gene were calculated using the geometric mean of housekeeping genes as normalizer. Relative expression levels were calculated as a variation of the Livak method [30] corrected for variation in amplification efficiency, as described by Fleige and Pfaffl [31].

Statistical analysis

Statistical analysis was carried out using the Statistical Analysis System (SAS) software package, version 9.1 (SAS Institute, USA). Sample size was determined by the POWER procedure of SAS. A sample size of 8 rats provided a statistical power of at least 80% for detecting 20% differences with a 2-tailed probability of P < 0.05. All data were checked for normal distribution and variance homogeneity and reported as means ± standard error (SE). Data were analysed using PROC MIXED to accommodate variance heterogeneity. If significant effects were obtained, least squares means were determined using the LSMEANS option and compared using the probability difference procedure (PDIFF adjust Tukey). The PROC CORR method was used to obtain Pearson’s correlation coefficients between n-3/n-6 PUFA ratio in erythrocytes and other parameters. P-values lower than 0.05 were considered statistically significant.

Results

Animal body composition

Body composition parameters of rats fed different n-3 LCPUFA sources are shown in Table 2. Most of the variables presented no changes across dietary groups, except total body weight gain that was found increased in Milk Fat in comparison to Schyzo (P < 0.05). Rats fed Nanno diet had higher values of daily feed intake than Fish Oil and Schyzo (P < 0.05). Carcass weight was found increased in Nanno relative to Schyzo (P < 0.05).

Plasma metabolites and inflammatory status

Biochemistry profile, markers of hepatic and renal function, and inflammation are also shown in Table 2. Total cholesterol, VLDL-cholesterol, TAG, total lipids and glucose were higher in Milk Fat group in comparison to the others (P < 0.001). Rats fed Schyzo diet had increased levels of LDL-cholesterol than the others (P < 0.01). LDL-C/HDL-C ratio was also higher in Schyzo group relative to Milk Fat and Fish Oil (P < 0.001). Although creatinine remained unchanged across dietary groups (P > 0.05), urea was found higher in Schyzo (P < 0.001). Regarding the hepatic markers, AST was increased in Schyzo and decreased in Nanno (P < 0.001). ALT and γ-GT were reduced in Nanno (P < 0.001) whereas ALP was reduced in Schyzo (P < 0.001). TNF-α presented no variations across dietary groups (P > 0.05), but IL-6 was increased in Schyzo fed rats (P < 0.001).

Fatty acid composition in faeces, liver and erythrocytes

FA composition in faeces is shown in Table 3. The fatty acid content was higher in Fish Oil and lower in Nanno (P < 0.001). Except for SFA, rats fed Nanno had increased excretion levels for MUFA (P < 0.001) (due to 16:1n-9=7, 17:1 and 18:1n-9 (oleic acid, OA) variations), PUFA, n-3 PUFA (P < 0.001) (due to 18:3n-3 (α-linolenic acid, ALA) and EPA variations) and n-6 PUFA (P < 0.001) (due to 18:2n-6 (linoleic acid, LA) and 20:4n-
6 (arachidonic acid, AA) variations). DHA was undetected in faeces.

FA composition in liver is presented in Table 4. The fatty acid content was lower in Schyzo when compared to Nanno ($P = 0.009$). SFA sum was decreased in Milk Fat fed rats relative to the others ($P < 0.001$), due to 15:0 ($P < 0.001$), 16:0 ($P < 0.001$), 17:0 ($P < 0.001$) and 18:0 (stearic acid, SA) ($P = 0.003$) variations. Rats fed Fish Oil had higher levels of total MUFA, in particular of 16:1\textit{n}-9 ($P = 0.008$), 16:1\textit{n}-7 ($P < 0.001$), OA ($P < 0.001$) and 20:1\textit{n}-9 ($P < 0.001$) than Milk Fat and Schyzo ($P < 0.001$), but identical to Nanno. PUFA and n-6 PUFA were increased in Milk Fat fed rats ($P < 0.001$) in comparison to the others due to LA, 20:2\textit{n}-6 and AA ($P < 0.001$) variations. n-3 sum and n-3/n-6 ratio were increased in Fish Oil relative to Milk Fat and Nanno ($P < 0.001$) due to changes in 20:4\textit{n}-3, EPA and DHA ($P < 0.001$). While EPA reached higher values in Fish Oil and Nanno ($P < 0.001$), DHA reached higher values in Fish Oil and Schyzo ($P < 0.001$).

FA composition in erythrocytes is shown in Table 5. It exhibited several resemblances to liver's, in particular for MUFA ($P < 0.001$), n-3 PUFA ($P < 0.001$) and n-3/n-6 ratio ($P < 0.001$). The same applies for EPA ($P < 0.001$) and DHA ($P < 0.001$). The n-6 PUFA reached the highest value in Milk Fat fed rats in comparison to the others due to LA, 20:2n-6 and AA ($P < 0.001$) variations. n-3 sum and n-3/n-6 ratio were increased in Fish Oil relative to Milk Fat and Nanno ($P < 0.001$) due to changes in 20:4n-3, EPA and DHA ($P < 0.001$). While EPA reached higher values in Fish Oil and Nanno ($P < 0.001$), DHA reached higher values in Fish Oil and Schyzo ($P < 0.001$).
Table 3 Total FAME (mg/g) and fatty acid composition (% total fatty acids) in faeces

|                  | Milk Fat Mean | SE  | Fish Oil Mean | SE  | Nanno Mean | SE  | Schyzo Mean | SE  | Significance |
|------------------|---------------|-----|---------------|-----|------------|-----|-------------|-----|--------------|
| Total FAME       | 111<sup>a</sup> | 17.2 | 126<sup>a</sup> | 9.72 | 64.2<sup>a</sup> | 4.04 | 108<sup>a</sup> | 11.1 | < 0.001      |
| Total SFA        | 84.7<sup>ab</sup> | 1.31 | 83.4<sup>b</sup> | 0.784 | 67.6<sup>c</sup> | 1.38 | 86.4<sup>a</sup> | 0.716 | < 0.001      |
| Total MUFA       | 10.2<sup>bc</sup> | 0.821 | 9.44<sup>b</sup> | 0.625 | 14.4<sup>c</sup> | 0.654 | 8.15<sup>b</sup> | 0.290 | < 0.001      |
| Total PUFA       | 3.26<sup>b</sup> | 0.433 | 2.39<sup>b</sup> | 0.126 | 10.2<sup>a</sup> | 0.741 | 2.95<sup>b</sup> | 0.172 | < 0.001      |
| Total n-3        | 1.01<sup>b</sup> | 0.156 | 0.754<sup>b</sup> | 0.103 | 6.13<sup>a</sup> | 0.499 | 0.766<sup>b</sup> | 0.125 | < 0.001      |
| Total n-6        | 2.25<sup>bc</sup> | 0.393 | 1.64<sup>c</sup> | 0.072 | 4.09<sup>a</sup> | 0.258 | 2.18<sup>b</sup> | 0.098 | < 0.001      |
| Total n-3/n-6    | 0.448<sup>bc</sup> | 0.505 | 0.460<sup>b</sup> | 0.075 | 1.50<sup>a</sup> | 0.055 | 0.351<sup>b</sup> | 0.055 | < 0.001      |

**p = 8 per group. ND, not detected. Total SFA = 11:0 + 13:0 + 14:0 + 15:0 + 16:0 + 17:0 + 18:0 + 19:0 + 20:0 + 20:1; Total MUFA = 16:1 + 16:2 + 17:1 + 18:1; Total PUFA = 18:2 + 18:3 + 19:0 + 20:0 + 20:1 + 20:2; Total n-3 = 16:3 + 18:3 + 20:1 + 21:0 + 22:1 + 22:2 + 22:3 + 22:5; Total n-6 = 18:2 + 20:2 + 20:4 + 20:5 + 20:6; **<sup>ab</sup>** Means in the same row with different superscripts are statistically different (PDIF adjust Tukey, *P* < 0.05)**
Table 4 Total FAME (mg/g) and fatty acid composition (% total fatty acids) in liver

|                  | Milk Fat Mean | Fish Oil Mean | Nanney Mean | Schizyo Mean | Significance |
|------------------|---------------|---------------|-------------|--------------|--------------|
| Total FAME       | 317±9.36      | 324±13.7      | 340±16.5    | 308±9.09     | 0.009        |
| Fatty acids      | P             | P             | P           | P            | P            |
| 12:0             | 0.103 ± 0.005 | 0.089 ± 0.007 | 0.129 ± 0.015 | 0.064 ± 0.005 | < 0.001      |
| 14:0             | 1.67 ± 0.077  | 1.91 ± 0.128  | 2.33 ± 0.137 | 1.19 ± 0.081  | < 0.001      |
| 15:0             | 0.39 ± 0.009  | 0.525 ± 0.017 | 0.596 ± 0.025 | 1.05 ± 0.053  | < 0.001      |
| 16:0             | 18.1 ± 0.186  | 24.2 ± 0.484  | 24.4 ± 0.510 | 24.3 ± 1.08   | < 0.001      |
| 16:1n-9          | 0.416 ± 0.033 | 0.622 ± 0.055 | 0.421 ± 0.031 | 0.392 ± 0.026 | 0.008        |
| 16:1n-9          | 2.13 ± 0.220  | 3.40 ± 0.402  | 4.58 ± 0.471 | 1.74 ± 0.151  | < 0.001      |
| 17:0iso-br       | 0.274 ± 0.005 | 0.365 ± 0.019 | 0.352 ± 0.014 | 0.292 ± 0.029 | < 0.001      |
| 17:0             | 0.221 ± 0.008 | 0.270 ± 0.015 | 0.346 ± 0.019 | 0.541 ± 0.025 | < 0.001      |
| 17:1             | 0.089 ± 0.005 | 0.109 ± 0.008 | 0.098 ± 0.007 | 0.104 ± 0.015 | 0.192        |
| 18:0             | 6.10 ± 0.369  | 6.62 ± 0.587  | 7.47 ± 0.652 | 8.19 ± 0.359  | 0.003        |
| 18:1n-9          | 21.7 ± 0.289  | 24.9 ± 0.595  | 21.2 ± 0.329 | 19.2 ± 0.578  | < 0.001      |
| 18:1n-7          | 2.00 ± 0.070  | 2.21 ± 0.060  | 2.25 ± 0.077 | 1.68 ± 0.056  | < 0.001      |
| 19:0iso-br       | 0.180 ± 0.006 | 0.227 ± 0.012 | 0.253 ± 0.016 | 0.157 ± 0.009 | < 0.001      |
| 18:2n-6          | 30.7 ± 0.471  | 18.3 ± 0.325  | 21.6 ± 0.417 | 21.1 ± 0.259  | < 0.001      |
| 19:0             | 0.412 ± 0.025 | 0.113 ± 0.005 | 0.167 ± 0.006 | 0.141 ± 0.002 | < 0.001      |
| 18:3n-3          | 2.57 ± 0.293  | 1.33 ± 0.086  | 1.50 ± 0.097 | 1.38 ± 0.055  | 0.003        |
| 18:4n-3          | 0.145 ± 0.025 | 0.114 ± 0.012 | 0.083 ± 0.021 | 0.093 ± 0.025 | 0.269        |
| 20:1n-9          | 0.222 ± 0.008 | 0.574 ± 0.029 | 0.097 ± 0.003 | 0.071 ± 0.005 | < 0.001      |
| 20:1n-7          | 0.103 ± 0.014 | 0.121 ± 0.018 | 0.099 ± 0.007 | 0.099 ± 0.012 | 0.688        |
| 20:2n-6          | 0.344 ± 0.021 | 0.126 ± 0.003 | 0.135 ± 0.004 | 0.100 ± 0.006 | < 0.001      |
| 20:3n-6          | 5.88 ± 0.257  | 2.51 ± 0.308  | 4.37 ± 0.254 | 5.40 ± 0.324  | < 0.001      |
| 20:4n-3          | 0.180 ± 0.060 | 0.272 ± 0.033 | 0.117 ± 0.013 | 0.103 ± 0.014 | < 0.001      |
| 20:5n-3          | 0.513 ± 0.075 | 2.17 ± 0.217  | 2.08 ± 0.209 | 0.909 ± 0.093 | < 0.001      |
| 22:4n-6          | 0.242 ± 0.014 | 0.053 ± 0.003 | 0.091 ± 0.005 | 0.100 ± 0.017 | < 0.001      |
| 22:5n-3          | 0.715 ± 0.081 | 1.18 ± 0.070  | 1.31 ± 0.112 | 0.409 ± 0.081 | < 0.001      |
| 22:6n-3          | 1.33 ± 0.067  | 3.85 ± 0.293  | 0.598 ± 0.051 | 6.43 ± 1.18   | < 0.001      |
| Others           | 3.04 ± 0.089  | 3.40 ± 0.120  | 3.05 ± 0.057 | 4.53 ± 0.265  | < 0.001      |

Partial sums and ratios

|                  | Mean | SE  | Mean | SE  | Mean | SE  |
|------------------|------|-----|------|-----|------|-----|
| Total SFA        | 27.4 | 0.288 | 34.4 | 0.846 | 36.1 | 0.980 | 35.9 | 1.55 |
| Total MUFA       | 26.7 | 0.492 | 32.0 | 0.955 | 28.7 | 0.780 | 23.3 | 0.756 |
| Total PUFA       | 42.8 | 0.378 | 30.2 | 1.04  | 32.1 | 0.885 | 36.3 | 1.83 |
| Total n-3        | 5.45 | 0.505 | 8.92 | 0.599 | 5.69 | 0.430 | 9.31 | 1.36 |
| Total n-6        | 37.2 | 0.604 | 21.0 | 0.555 | 26.1 | 0.544 | 26.7 | 0.554 |
| n-3/n-6          | 0.148 | 0.017 | 0.423 | 0.022 | 0.217 | 0.013 | 0.343 | 0.044 |

Comparison to the others (P < 0.001), due to variations in LA (P < 0.001), 20:2n-6 (P < 0.001), AA (P < 0.001) and 22:4n-6 (P < 0.001). The SFA sum was similar across diets (P > 0.05), although small changes were observed for 15:0, 17:0, 18:0, 19:0, 20:0 and 22:0 (P < 0.001).
### Table 5 Total FAME (mg/g) and fatty acid composition (% total fatty acids) in erythrocytes

|                  | Milk Fat | Fish Oil | Nanno | Schizo | Significance |
|------------------|----------|----------|-------|--------|--------------|
|                  | Mean     | SE       | Mean  | SE     | Mean         | SE     | 8.12 | 0.718 | 10.6 | 0.455 | 10.8 | 0.320 | 11.7 | 0.889 | 0.521 |
| **Fatty acids**  |          |          |       |        |              |       |      |       |       |       |       |       |       |
| 14:0             | 0.550    | 0.052    | 0.680 | 0.044  | 0.730         | 0.037 | 0.780 | 0.170 | 0.068 |
| 15:0             | 0.360a   | 0.024    | 0.430a| 0.027  | 0.450b        | 0.011 | 0.940 | 0.066 | <0.001|
| 16:0             | 2.34     | 0.071    | 2.31  | 0.062  | 2.61          | 0.094 | 2.24  | 0.111 | 0.050 |
| 16:1n-9          | 0.120b   | 0.017    | 0.190a| 0.007  | 0.160b        | 0.005 | 0.160b| 0.012 | 0.005 |
| 16:1n-7          | 0.320a   | 0.033    | 0.520ab| 0.035  | 0.720a        | 0.068 | 0.420c| 0.040 | <0.001|
| 17:0             | 0.260c   | 0.006    | 0.270c| 0.007  | 0.300b        | 0.004 | 0.330a| 0.005 | <0.001|
| 17:1             | 0.460c   | 0.010    | 0.440c| 0.010  | 0.580b        | 0.007 | 0.760a| 0.009 | <0.001|
| 18:0             | 0.300b   | 0.022    | 0.320ab| 0.029  | 0.350ab       | 0.030 | 0.390a| 0.016 | 0.009 |
| 18:1             | 0.230a   | 0.012    | 0.210a| 0.012  | 0.190a        | 0.015 | 0.150b| 0.008 | <0.001|
| 18:2             | 0.430c   | 0.034    | 0.410c| 0.038  | 0.480b        | 0.035 | 0.890c| 0.042 | <0.001|
| 18:3             | 0.110b   | 0.006    | 0.090b| 0.006  | 0.100b        | 0.005 | 0.130a| 0.013 | 0.047 |
| 18:4             | 0.080d   | 0.005    | 0.040d| 0.004  | 0.070b        | 0.009 | 0.090d| 0.012 | <0.001|
| 19:0             | 0.900c   | 0.009    | 0.300b| 0.002  | 0.080b        | 0.002 | 0.080d| 0.005 | <0.001|
| 18:3n-3          | 0.140c   | 0.019    | 0.090b| 0.004  | 0.060c        | 0.005 | 0.070c| 0.011 | <0.001|
| 20:0             | 0.110b   | 0.006    | 0.090b| 0.006  | 0.100b        | 0.005 | 0.130a| 0.013 | 0.047 |
| 20:1n-9          | 0.080d   | 0.005    | 0.040d| 0.004  | 0.070b        | 0.009 | 0.090d| 0.012 | <0.001|
| 20:1n-7          | 0.077    | 0.006    | 0.090d| 0.007  | 0.086         | 0.009 | 0.085 | 0.004 | 0.339 |
| 20:2n-6          | 0.370a   | 0.023    | 0.200b| 0.024  | 0.170b        | 0.009 | 0.190b| 0.016 | <0.001|
| 20:4n-6          | 0.250b   | 0.017    | 0.290b| 0.023  | 0.550b        | 0.021 | 0.390f| 0.281 | <0.001|
| 20:5n-6          | 0.410ab  | 0.036    | 0.080b| 0.012  | 0.060b        | 0.002 | 0.490b| 0.110 | <0.001|
| 20:5n-3          | 0.260c   | 0.026    | 0.300b| 0.114  | 2.33d         | 0.054 | 0.470c| 0.254 | <0.001|
| 21:0             | 0.200b   | 0.026    | 0.270b| 0.032  | 0.280b        | 0.009 | 0.390c| 0.354 | 0.002 |
| 22:4n-6          | 1.51d   | 0.118    | 0.250d| 0.023  | 0.550b        | 0.021 | 0.390f| 0.281 | <0.001|
| 22:5n-6          | 0.340d   | 0.021    | 0.100c| 0.007  | 0.140d        | 0.008 | 1.75c | 1.50  | <0.001|
| 22:5n-3          | 1.94d   | 0.426    | 2.55d | 0.177  | 3.50c         | 0.094 | 0.950f| 0.654 | <0.001|
| 24:0             | 0.890    | 0.089    | 0.120  | 0.097  | 0.240d        | 0.035 | 5.78b | 0.484 | <0.001|
| 24:1n-9          | 0.452    | 0.046    | 0.570 | 0.070  | 0.400         | 0.032 | ND   | -     | 0.106 |
| Others           | 1.69b    | 0.029    | 2.37a | 0.080  | 2.47a         | 0.026 | 1.76b | 0.057 | <0.001|

**Partial sums and ratios**

|                  | Total SFA | Total MUFA | Total PUFAs | Total n-3 | Total n-6 | n-3/n-6 |
|------------------|-----------|------------|-------------|-----------|-----------|---------|
|                  | 43.0      | 11.4b      | 16.8b       | 7.68c     | 35.9a     | 0.214a  |

**n = 8 per group, ND, not detected. Total SFA = 14.0 + 16:0 + 16:1n-7 + 17:1 + 18:1n-9 + 18:2n-6 + 20:1n-9 + 20:1n-7 + 24:1n-9; Total MUFA = 16:1n-9 + 16:1n-7 + 17:1 + 18:1n-9 + 18:2n-6 + 20:1n-9 + 20:1n-7 + 24:1n-9; Total PUFAs = 16:3n-4 + 16:4n-3 + 16:5n-3 + 16:3n-3 + 18:2n-6 + 18:3n-3 + 20:2n-6 + 20:4n-3 + 20:5n-3 + 22:4n-6 + 22:5n-6 + 22:5n-3 + 22:6n-3 + 22:6n-3; Total n-3 = 16:3n-3 + 16:4n-3 + 18:3n-3 + 20:4n-3 + 20:5n-3 + 22:5n-3 + 22:6n-3; Total n-6 = 18:2n-6 + 20:2n-6 + 20:4n-6 + 22:4n-6 + 22:5n-6. **Means in the same row with different superscripts are statistically different (PDIFF adjust Tukey, P < 0.05)**
Fatty acid composition and major phospholipid classes in brain

FA composition in brain is presented in Table 6. Whereas the liver displayed the highest number of variations depending on diet, the brain tissue was less responsive. SFA, MUFA, PUFAs and n-3 PUFAs were unchanged across dietary treatments \( (P > 0.05) \). n-6 PUFAs was higher in Milk Fat in comparison to Fish Oil \( (P = 0.018) \), but identical to Nanno and Schyzo, most at the expenses of LA \( (P = 0.011) \) and 22:4n-6 \( (P = 0.031) \). The \( \text{n-3/n-6} \) ratio reached the highest value in Fish Oil fed rats relative to Milk Fat and Nanno \( (P = 0.000) \). As expected, EPA was not detected in Milk Fat and it was best incorporated in Fish Oil fed rats \( (P = 0.000) \). DHA did not vary across diets \( (P > 0.05) \).

The major phospholipids classes in brain are also shown in Table 6. In comparison to Milk Fat, Nanno fed rats had increased non-polar lipids (NPL) but decreased phosphatidylcholine (PC) \( (P < 0.05) \). No additional changes were found for phosphatidylethanolamine (PE) and phosphatidylserine (PS) fractions across dietary groups \( (P > 0.05) \).

Behaviour, serotonin and catecholamines

The FST outcomes are presented in Table 7 along with serotonin and catecholamines levels in plasma. Rats fed Nanno and Schyzo diets spent more time floating than rats fed Fish Oil \( (P < 0.05) \). In turn, Nanno had more time immobile than Schyzo \( (P < 0.05) \). Climbing and swimming were unchanged \( (P < 0.05) \) by diet. Adrenalin was increased in Schyzo relative to Milk Fat \( (P < 0.05) \). Fish Oil fed rats had higher dopamine levels than Nanno \( (P < 0.05) \). Serotonin and noradrenalin presented similar values across dietary treatments \( (P < 0.05) \).

Neuromodulation transcriptional profile

The transcriptional profile of HT1A, HT2A, BDNF, CREB, TNF-\( \alpha \) and IL-6 in the hippocampus of rats fed Milk Fat, Fish Oil, Nanno and Schyzo diets are shown in Fig. 1. A similar pattern of variations was found for HT1A, HT2A and CREB being these genes consistently downregulated in Milk Fat in comparison to n-3 LCPUFA diets \( (P < 0.05) \). BDNF gene was upregulated by Schyzo diet \( (P < 0.05) \). The gene expression levels of IL-6 were equally higher in Fish Oil and Nanno fed rats, and lower in Schyzo \( (P < 0.05) \). mRNA levels of TNF-\( \alpha \) were similar across dietary groups \( (P > 0.05) \). Moreover, mRNA expression levels of HT1A, HT2A and CREB were moderately \( (0.7 \geq r \geq 0.3) \) positively correlated with \( \text{n-3/n-6} \) PUFAs ratio in erythrocytes \( (r = 0.532, P = 0.002; r = 0.673, P < 0.001; r = 0.539, P = 0.001, \text{respectively}) \).
|                 | Milk Fat |       | Fish Oil |       | Nanno |       | Schyzo |       | Significance |
|----------------|----------|-------|----------|-------|-------|-------|--------|-------|--------------|
|                | Mean SE  | Mean SE | Mean SE  | Mean SE | Mean SE | Mean SE | Mean SE | Mean SE |              |
| **Total FAME** | 153 8.04 | 175 12.1 | 169 8.08 | 157 5.01 | 0.354  |
| Fatty acids    |          |        |          |        |        |        |        |        |              |
| 14:0           | 0.172 0.010 | 0.156 0.021 | 0.147 0.016 | 0.144 0.013 | 0.365  |
| 16:0anteiso    | 2.23 0.101 | 2.14 0.089 | 2.36 0.180 | 2.13 0.863 | 0.641  |
| 16:0           | 18.9 0.819 | 18.6 1.42 | 18.9 1.26 | 17.6 0.111 | 0.692  |
| 16:1n-9        | 0.112 0.006 | 0.120 0.008 | 0.114 0.007 | 0.093 0.021 | 0.293  |
| 16:1n-7        | 0.380 0.019 | 0.444 0.039 | 0.407 0.025 | 0.379 0.021 | 0.406  |
| 16:3n-4        | 0.239 0.024 | 0.284 0.025 | 0.217 0.028 | 0.246 0.033 | 0.348  |
| 16:3n-3        | 3.90 0.055 | 4.10 0.086 | 4.36 0.259 | 4.03 0.057 | 0.095  |
| 16:4n-3        | 1.45 0.119 | 1.40 0.066 | 1.44 0.057 | 1.42 0.086 | 0.963  |
| 18:0           | 18.9 0.382 | 19.6 0.181 | 19.9 0.332 | 19.2 0.283 | 0.174  |
| 18:1n-9        | 15.8 0.427 | 16.6 0.277 | 15.9 0.246 | 16.1 0.483 | 0.238  |
| 18:1n-7        | 3.03 0.095 | 2.93 0.041 | 3.01 0.031 | 2.88 0.085 | 0.239  |
| 18:2n-6        | 1.04 a 0.064 | 0.920 ab 0.038 | 0.810 b 0.028 | 0.830 ab 0.082 | 0.011  |
| 19:0           | 0.047 0.005 | 0.051 0.002 | 0.052 0.004 | 0.055 0.002 | 0.420  |
| 18:4n-3        | 0.051 0.004 | 0.045 0.008 | 0.059 0.006 | 0.052 0.002 | 0.569  |
| 20:0           | 0.459 0.069 | 0.437 0.036 | 0.443 0.035 | 0.442 0.038 | 0.994  |
| 20:1n-9        | 1.44 0.286 | 1.33 0.144 | 1.36 0.103 | 1.44 0.172 | 0.962  |
| 20:1n-7        | 0.449 0.077 | 0.398 0.037 | 0.413 0.030 | 0.430 0.044 | 0.915  |
| 20:2n-6        | 0.151 0.019 | 0.110 0.008 | 0.120 0.007 | 0.097 0.008 | 0.050  |
| 20:4n-6        | 10.1 0.284 | 9.28 0.209 | 9.60 0.476 | 9.59 0.181 | 0.202  |
| 20:5n-3        | ND       | –      | 0.070 a 0.006 | 0.040 b 0.004 | 0.020 c 0.003 | 0.000  |
| 22:0           | 0.478 0.074 | 0.407 0.049 | 0.429 0.055 | 0.456 0.051 | 0.844  |
| 22:1n-11       | 0.221 0.045 | 0.176 0.024 | 0.197 0.019 | 0.199 0.031 | 0.810  |
| 22:1n-9        | 0.101 0.004 | 0.113 0.011 | 0.115 0.015 | 0.123 0.025 | 0.552  |
| 23:0           | 0.241 0.013 | 0.235 0.023 | 0.279 0.035 | 0.247 0.018 | 0.736  |
| 22:4n-6        | 3.21 a 0.144 | 2.52 b 0.185 | 2.98 b 0.183 | 2.73 ab 0.163 | 0.031  |
| 22:5n-6        | 0.804 0.099 | 0.532 0.187 | 0.719 0.312 | 0.940 0.061 | 0.192  |
| 22:5n-3        | 0.280 ab 0.064 | 0.340 a 0.019 | 0.410 a 0.036 | 0.160 b 0.008 | 0.000  |
| 24:0           | 1.11 0.141 | 0.893 0.115 | 0.991 0.163 | 0.999 0.099 | 0.705  |
| 22:6n-3        | 11.4 0.601 | 13.0 0.707 | 10.9 0.857 | 13.1 0.724 | 0.084  |
| 24:1n-9        | 1.43 0.252 | 1.14 0.162 | 1.27 0.211 | 1.25 0.167 | 0.800  |
| Others         | 1.88 a 0.119 | 1.58 b 0.084 | 2.13 a 0.158 | 2.66 a 0.166 | 0.000  |
| **Partial sums and ratios** |          |        |          |        |        |        |        |        |              |
| Total SFA      | 42.6 0.891 | 42.6 1.40 | 43.5 1.40 | 41.2 1.01 | 0.634  |
| Total MUFA     | 23.0 1.07 | 23.2 0.545 | 22.8 0.311 | 22.9 0.814 | 0.886  |
| Total PUFA     | 32.5 0.871 | 32.6 1.09 | 31.6 1.34 | 33.2 1.03 | 0.787  |
| Total n-3      | 17.0 0.536 | 19.0 0.835 | 17.2 0.816 | 18.8 0.697 | 0.084  |
| Total n-6      | 14.5 a 0.436 | 12.8 b 0.339 | 13.5 ab 0.570 | 13.3 ab 0.332 | 0.018  |
| n-3/n-6        | 1.18 a 0.035 | 1.48 a 0.048 | 1.27 bc 0.036 | 1.42 ab 0.025 | 0.000  |
| **Major phospholipid classes** |          |        |          |        |        |        |        |        |              |
| NPL            | 31.1 b 0.934 | 34.0 ab 1.37 | 36.0 a 0.861 | 33.6 ab 2.73 | 0.223  |
even if these determinations were performed in different tissues. IL-6 has been reported to increase hepatic synthesis of cholesterol [41] which possibly explains the high levels of cholesterol found in Schyzo fed rats relative to the other n-3 LCPUFA diets.

The FA profile in faeces was assessed to determine FA loss, compared to the amount provided by diet. The fatty acid content was higher in Fish Oil and lower in Nanno which means that Nanno fed rats had a higher absorption of FA in the organism. *Nannochloropsis* is indeed efficiently incorporated into the blood, liver and brain lipids of rats [32]. EPA was found higher in Nanno and residual in Fish Oil, which concurs with diet composition. The same explanation applies to Milk Fat or Schyzo with no traces of EPA in faeces. As expected, DHA was not detected in faeces of any dietary group since PUFA was lower in faeces, indicating a better systemic FA bioavailability, showed similar alterations to the liver, although in a lower magnitude. PUFA levels were higher than MUFA, which was expected since PUFA was lower in faeces, indicating a better absorption of these FA by the organism. Within PUFA, n-6 was found higher over n-3, which is also logical because all diets had higher n-6 relative to n-3. ARA concentrations were elevated in rats fed high levels of LA, likely as a result of higher ARA synthesis rates [48]. EPA, although found in residual levels (less than 1%), was higher in Fish Oil than in Nanno fed rats and this result contradicts diet composition. The reason for this finding is that EPA was more.

### Table 6 Total FAME (mg/g), fatty acid composition (% total fatty acids) and major phospholipid classes in brain (Continued)

|          | Milk Fat |          | Fish Oil |          | Nanno |          | Schyzo |          | Significance |
|----------|----------|----------|----------|----------|-------|----------|--------|----------|--------------|
|          | Mean     | SE       | Mean     | SE       | Mean  | SE       | Mean   | SE       | Mean         |
| PE       | 33.4     | 0.732    | 33.4     | 0.956    | 31.9  | 0.621    | 34.3   | 1.55     | 0.288        |
| PS       | 21.9     | 1.21     | 20.5     | 2.03     | 20.5  | 0.658    | 18.3   | 1.89     | 0.468        |
| PC       | 13.6\(^a\) | 0.141    | 12.1\(^m\) | 0.706    | 11.6\(^m\) | 0.523 | 13.9\(^m\) | 0.776 | 0.016 |

\(^{n=8}\) per group. ND, not detected. NPL, non-polar lipids; PE, phosphatidylethanolamine; PS, phosphatidylserine; PC, phosphatidylcholine. Total SFA = 14:0 + 16:0 + 18:0 + 19:0 + 20:0 + 22:0 + 23:0 + 24:0; Total MUFA = 14:1 + 15:1 + 16:1 + 17:1 + 19:1 + 20:1; Total PUFA = 16:3 + 18:3 + 18:4 + 20:3 + 20:4 + 22:3 + 22:4 + 22:5 + 22:6.

### Table 7 FST outcomes, serotonin and catecholamines in plasma

|          | Milk Fat |          | Fish Oil |          | Nanno |          | Schyzo |          | Significance |
|----------|----------|----------|----------|----------|-------|----------|--------|----------|--------------|
|          | Mean     | SE       | Mean     | SE       | Mean  | SE       | Mean   | SE       | Mean         |
| Climbing (s) | 595     | 9.75     | 75.5     | 10.1     | 57.0  | 14.0     | 68.3   | 14.2     | 0.628        |
| Swimming (s) | 119     | 20.1     | 125      | 24.3     | 82.1  | 13.3     | 135    | 18.7     | 0.110        |
| Floating (s) | 58.4\(^m\) | 8.37    | 37.7\(^m\) | 5.82     | 78.9\(^m\) | 14.2 | 67.9\(^m\) | 6.41  | 0.006        |
| Immobile (s) | 67.7\(^m\) | 19.1    | 58.8\(^m\) | 21.3     | 76.0\(^m\) | 13.5 | 24.8\(^m\) | 6.36  | 0.006        |
| Total Movement (s) | 179     | 21.7     | 200      | 26.1     | 150   | 22.7     | 208    | 10.3     | 0.137        |
| Total Immobile (s) | 126     | 21.4     | 104      | 25.8     | 155   | 22.6     | 96.7   | 9.96     | 0.025        |
| Serotonin (µg/l) | 76.3     | 32.8     | 21.4     | 9.73     | 49.9  | 13.9     | 114    | 41.1     | 0.061        |
| Noradrenalin (ng/l) | 1257    | 89.1     | 1377     | 128      | 1442  | 152      | 1806   | 184      | 0.082        |
| Adrenalin (ng/l) | 1826\(^m\) | 402     | 3098\(^m\) | 561     | 4117\(^m\) | 1296 | 4889\(^m\) | 904   | 0.016        |
| Dopamine (ng/l) | 78.9\(^m\) | 18.4    | 115\(^m\) | 23.5     | 43.1\(^m\) | 10.5 | 58.4\(^m\) | 14.4  | 0.047        |

\(^{n=8}\) per group. \(^{a,b,c}\) Means in the same row with different superscripts are statistically different (PDFF adjust Tukey, \(P<0.05\)).
converted to 22:5n-3, a downstream product of EPA in Nanno fed rats. DHA was found higher in Schyzo and lower in Nanno which was expected because Nanno diet had no DHA. The residual levels found might be due to the biosynthesis of DHA from the n-3 precursor (ALA) [49] or by EPA in the Nanno group [50]. The same conversion might also have happened in Milk Fat group. Taking into account the highest percentage of n-3 PUFA and EPA, and also a high percentage of DHA in erythrocytes, Fish Oil is proven the best dietary source for systemic incorporation of these FA in the organism.

On a per-weight basis, brain is the tissue richest in lipids [51]. It is the most conservative organ in terms of DHA uptake [43, 44] where it composes ~10% of total FA [52]. DHA is essential for maintaining normal brain structure, function and metabolism and its concentration depends on dietary DHA content as well as liver synthesis from its shorter chain nutritionally essentialPUFA precursor ALA [49]. In fact, DHA synthesis directly in brain tissues is very low [53]. Herein, the non-variation of DHA reinforces the notion that DHA is rapidly absorbed and retained in brain cell membranes [42]. We speculate that the levels found might have been incorporated prior to the administration of DHA, through diet [54]. Any ability to detect changes in EPA in the brain is unexpected. EPA is rapidly and extensively β-oxidised upon entry into the brain [55]. Anyway, we found that rats fed Fish Oil had the highest % of EPA, followed by Nanno and Schyzo groups. These data are in accordance with EPA levels found in erythrocytes and faeces, in which Fish Oil group presented the highest and lowest % of EPA, respectively. The undetected EPA in Milk Fat fed rats correlates well with diet composition.

Fig. 1 Effect of dietary treatments on the relative expression levels of serotonin 5-HT1A receptor (HT1A), serotonin 5-HT2A receptor (HT2A), brain-derived neurotrophic factor (BDNF), cAMP responsive element binding protein (CREB), tumour necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) in the hippocampus. Means ± standard error (SE). Means with different letters are significantly different (PDIFF adjust Tukey, P < 0.05)
FA composition of the two major phospholipids classes, PE and PC, was found to be specific: PC contains mostly SFA and 18:1 fatty acids, while PE is rich in PUFA [56]. Changes in SFA/PUFA ratio are likely to influence cellular function, which could impair neurophysiological performances [57, 58]. Even if we failed to characterise the FA composition in brain phospholipid classes, our data suggest a compensatory mechanism of reduced PC fraction while increasing NPL (the majority of which is composed of cholesterol) between Nanno and Milk Fat dietary groups. The lipid class-dependent nature of these variations reflects generally differences in intake and metabolism [59]. Lamaziere et al. [51] reported that the provision of fish oil to rats did not modify PS, in accordance to our data, but increased the proportion of DHA-containing PC. The PE fraction, in which DHA accounts for around 25% (wt%) of total FA [60] was similarly altered by n-3 PUFA administration [51], in contrast to our findings.

With respect to FST parameters, it would be expected higher immobile and floating times in Milk Fat (without n-3 LCPUFA supplementation) fed rats because these behaviours are recognised as passive and non-active indicators, respectively [26]. Regarding immobility, Nanno fed rats spent more time immobile than Schyzo. DHA has been referred as a possible nutrient for retarding depression and anxiety, supporting the lower immobility time found in Schyzo. Notwithstanding, the immobility time found in Milk Fat was lower than expected and not consistent with the hypothesis initially proposed or with other studies [5, 61]. The lack of positive behaviour in Nanno fed rats can be explained by the high levels of EPA found in faeces. Regarding floating time, Nanno and Schyzo were similar to each other, but higher than Fish Oil. Once more, this possibly indicates that single EPA or DHA are not as beneficial as EPA + DHA, in agreement with observations by Mozaffarian and Wu [62] on cardiovascular health. The only setback is that floating time was also identical between Milk Fat and Fish Oil. In fact, Milk Fat behavioural outcomes were similar to other dietary groups. The presence of DHA in brain of rats fed Milk Fat, in identical amounts to those of n-3 LCPUFA enriched diets, can help to explain this similarity.

Adrenalin is a stress hormone [63] whose levels seem to decrease with fish oil administration [64, 65]. A tendency for reduced adrenalin was observed in Fish Oil fed rats relative to Nanno and Schyzo, in accordance with literature [64, 65]. However, Milk Fat group had the lowest adrenalin levels but this diet did not contain EPA or DHA. Moreover, its levels are similar to those found in both Fish Oil and Nanno, but different from Schyzo, leading us to the assumption that neither EPA nor DHA affect adrenalin system, with EPA having a less predominant role, contradicting other reports. On the topics of catecholamines regulation, low levels of dopamine have been associated with PUFA deficiency [65–67]. Higher levels of dopamine were found in Fish Oil group whereas lower were found in Nanno. Therefore, it can be assumed that EPA alone has a smaller impact on regulating dopaminergic system, than combined with DHA.

HT1A and HT2A are related to neural function. Levant et al. [68] have shown that rats with low levels of DHA in brain have less serotonin (5-HT) and higher hippocampal density of 5-HT1A. Serotonin in plasma was found similar across dietary groups although a tendency for high levels were found in Schyzo fed rats, which concurs with diet composition. The transcriptional profile of HT1A and HT2A was consistently upregulated by EPA, DHA or both FA, rather than only by DHA. Accordingly, more research on this subject is required. The variation of CREB expression is positive, given its role in learning and memory, brain traumas recovery and stress [69]. Although not consensual [68], it corroborates the literature pointing towards the normalization of CREB by n-3 LCPUFA enriched diets. Also, HT1A, HT2A and CREB mRNA levels in hippocampus were found positively correlated with n-3/n-6 PUFA in erythrocytes. This ratio is considered a biomarker of systemic inflammation [70, 71] consolidating, once again, the neuroprotective effects of EPA and DHA. CREB is also a transcription factor contributing for BDNF regulation [72, 73]. This later gene was found powerfully expressed by individual DHA.

**Conclusions**

The underlying hypothesis of this study was that EPA and DHA would have distinct neurobiological effects, if ingested singly or combined, using alternative marine lipid sources as n-3 LCPUFA rich microalgae in Wistar rats. FST revealed the potential benefit of fish oil (EPA + DHA) compared to microalgae oils (EPA or DHA singly). These results could be ascribed to high concentrations of systemic dopamine and n-3 LCPUFA incorporation in liver and erythrocytes, suggesting that fish oil is a better dietary source for FA deposition in the organism. Moreover, each tissue, liver, erythrocytes and brain, showed a particular FA profile with specific traits. Another positive impact of a diet rich in both EPA and DHA was the mitigation of plasma metabolites unbalance, in particular through reduction of total lipids and LDL-C/HDL-C ratio. In turn, EPA provided by _Nannochloropsis_ microalga had similar results, although with a lower
magnitude as EPA and DHA combined, in opposition to DHA provided by *Schizochytrium* microalga, allowing us to conclude that the protective effects on plasma lipid profile might be due, to a large extent, to EPA action. Apart from the positive variation of BDNF mRNA levels by DHA alone, the combination of EPA and DHA can provide protection against reduced plasticity and impaired learning ability by up-regulating HT1A, HT2A and CREB genes in the hippocampus. Taken together, a diet enriched in EPA + DHA form seems more adequate for health promotion, in various critical domains of neurophysiology and lipid metabolism, which can benefit, in the long run, neuronal structure and function.

**Abbreviations**

- y-GT: gamma glutamyl transferase
- AA: arachidonic acid
- ALA: α-linolenic acid
- ALP: alkaline phosphatase
- ALT: alanine aminotransferase
- AST: aspartate aminotransferase
- BDNF: brain-derived neurotrophic factor
- CREB: cAMP responsive element binding protein
- DHA: docosahexaenoic acid
- EPA: eicosapentaenoic acid
- FA: fatty acid
- FAME: fatty acid methyl esters
- FST: forced swimming test
- HT1A: serotonin 5-HT1A receptor
- HT2A: serotonin 5-HT2A receptor
- IL-6: interleukin-6
- LA: linoleic acid
- LCSPUFA: n-3 long chain polyunsaturated fatty acids
- NPL: non-polar lipids
- PC: phosphatidylcholine
- PE: phosphatidylethanolamine
- PS: phosphatidylserine
- TAG: triacylglycerols
- TNF-α: tumour necrosis factor
- α

**Acknowledgments**
The authors acknowledge Júlia Ferreira from IPMA regarding lipid analyses.

**Funding**
This study was supported by the Spanish Ministry of Science and Innovation through “Structural lipids: novel dietary strategies for improving human health” grant (AGL2007/07029) and by Fundação para a Ciência e a Tecnologia (FCT, Lisbon, Portugal) through CIISA project (UID/CVT/00276/2013). PAL is a researcher from Incentivo 2014 project (AGR/UI0273/2014). SVM, CC and CA are recipients of individual fellowships from FCT (SFRH/BPD/63019/2009, SFRH/BPD/102689/2014 and SFRH/BPD/64951/2009, respectively).

**Availability of data and materials**
The datasets analysed during the current study are available from the corresponding author on reasonable request.

**Authors’ contributions**
PAL, SVM and MSM performed the animal experiment. JLGG and JM performed the behaviour test. PAL, SVM, CMA, MCP and RMAP conducted the laboratory work. PAL, CC and CA prepared the manuscript. NMB, JLGG and JM performed the animal experiment. PAL, SVM and MSM performed the lipid analysis. JLGG and JM performed the statistical analysis. NMB, JLGG and JM performed the western blot analysis. PAL, SVM, CMA, MCP and RMAP conducted the biochemical analysis. PAL, CC and CA prepared the manuscript.

**Ethics approval**

The experimental procedures were reviewed by the Ethics Commission of CIISA/FFW and approved by the Animal Care Committee of the National Veterinary Authority (Direcção-Geral de Alimentação e Veterinária, Portugal), following the appropriate European Union guidelines (2010/63/EU Directive) to minimise animal suffering.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**References**

1. Harman D. The aging process (free radicals/evolution/antioxidants/ degenerative diseases/longevity). PNAS. 1981;78:7124–8.
2. WHO. World Health Organization. Ageing and life course: interesting facts about ageing. 2012 (available online at http://www.who.int/ageing/about/facts/en/).
3. Klenk I, Keil U, Jaensch A, Christiansen MC, Nagel G. Changes in life expectancy 1950–2010: contributions from age- and disease-specific mortality in selected countries. Popul Health Metrics. 2016;14:20.
4. Dyll SC, Michaelis-Titus AT. Neurological benefits of omega-3 fatty acids. NeuroMolecular Med. 2008;10:219–35.
5. Ferraz AC, Delattre AM, Almendra RG, Sonagli M, Borges C, Araujo P, Andersen ML, Tufik S, Lima MM. Chronic ω-3 fatty acids supplementation promotes beneficial effects on anxiety, cognitive and depressive-like behaviors in rats subjected to a restraint stress protocol. Behav Brain Res. 2012;219:116–22.
6. Cutuli D, De Bartolo P, Caporali P, Laricchiuta D, Foti F, Rondi M, Rossi C, Neri C, Spalletta G, Caltagirone C, Farioli-Vecchioli S, Petrosini L. n-3 polyunsaturated fatty acids supplementation enhances hippocampal functionality in aged mice. Front Aging Neurosci. 2014;6:20. https://doi.org/10.3389/fragi.2014.00220.
7. Moffino A, Giola G, Rossi Fanel F, Muciarollo M. The role for dietary omega-3 fatty acids supplementation in older adults. Nutrients. 2014;6:4058–72.
8. Logan AC. Neurobehavioral aspects of omega-3 fatty acids: possible mechanisms and therapeutic value in major depression. Altern Med Ver. 2003;8:410–25.
9. Chalon S, Delon-Vancasselt S, Belzung C, Guilloteau D, Leguisquet AM, Benard JC, Durand G. Dietary fish oil affects monoaminergic neurotransmission and behavior in rats. Nutr Neurosci. 1998;1:116–25.
10. Burdge GC, Finnegan YE, Neri C, Spalletta G, Caltagirone C, Farioli-Vecchioli S, Petrosini L. n-3 polyunsaturated fatty acids supplementation enhances hippocampal functionality in aged mice. Front Aging Neurosci. 2014;6:20. https://doi.org/10.3389/fragi.2014.00220.
11. Cutuli D, De Bartolo P, Caporali P, Laricchiuta D, Foti F, Rondi M, Rossi C, Neri C, Spalletta G, Caltagirone C, Farioli-Vecchioli S, Petrosini L. n-3 polyunsaturated fatty acids supplementation enhances hippocampal functionality in aged mice. Front Aging Neurosci. 2014;6:20. https://doi.org/10.3389/fragi.2014.00220.
12. Adarme-Vega TC, Thomas-Hall SR, Schenk PM. Towards sustainable sources for omega-3 fatty acids production. Curr Opin Biotechnol. 2014;26:14–8.
13. Winwood RJ. Recent developments in the commercial production of DHA and EPA rich oils from micro-algae. OCL. 2013;20:D604.
14. Burdge GC, Finnegan YE, Minihane AM, Williams CM, Wootton CA. Effect of altered dietary n-3 fatty acid intake upon plasma lipid fatty acid composition, conversion of [13C]α-linolenic acid to longer-chain fatty acids and partitioning towards beta-oxidation in older men. Brit J Nutr. 2003;90:311–21.
15. Calder PC. Mechanisms of action of (n-3) fatty acids. Nutr J. 2012;11:529–35.
16. Adarme-Vega TC, Thomas-Hall SR, Schenk PM. Towards sustainable sources for omega-3 fatty acids production. Curr Opin Biotechnol. 2014;26:14–8.
17. Winwood RJ. Recent developments in the commercial production of DHA and EPA rich oils from micro-algae. OCL. 2013;20:D604.
18. Marangoni F, Poli A. n-3 fatty acids: functional differences between food intake, oral supplementation and drug treatments. Int J Cardiol. 2013;170:S12–5.
19. Dyll SC. Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. Front Aging Neurosci. 2015;7:52.
20. Bozzatello P, Brignolo E, De Grandi E, Bellino S. Supplementation with long chain omega-3 fatty acids and partitioning towards beta-oxidation in older men. Brit J Nutr. 2003;90:311–21.
21. Calder PC. Mechanisms of action of (n-3) fatty acids. Nutr J. 2012;11:529–35.
22. Adarme-Vega TC, Thomas-Hall SR, Schenk PM. Towards sustainable sources for omega-3 fatty acids production. Curr Opin Biotechnol. 2014;26:14–8.
23. Winwood RJ. Recent developments in the commercial production of DHA and EPA rich oils from micro-algae. OCL. 2013;20:D604.
24. Marangoni F, Poli A. n-3 fatty acids: functional differences between food intake, oral supplementation and drug treatments. Int J Cardiol. 2013;170:S12–5.
25. Dyll SC. Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. Front Aging Neurosci. 2015;7:52.
26. Bozzatello P, Brignolo E, De Grandi E, Bellino S. Supplementation with omega-3 fatty acids in psychiatric disorders: a review of literature data. J Clin Med. 2016;5:67. https://doi.org/10.3390/jcm5080067.
27. Russell FD, Bürgin-Mauner C. Distinguishing health benefits of eicosapentaenoic and docosahexaenoic acids. Mar Drugs. 2012;10:2353–59.
28. Song C, Shieh CH, Wu YS, Kaluwe A, Galkwad S, Su KP. The role of omega-3 polyunsaturated fatty acids eicosapentaenoic and docosahexaenoic acids in...
the treatment of major depression and Alzheimer’s disease: acting separatively or synergistically? Prog Lipid Res. 2016;62:41–54.

19. AOAC. Official Methods of Analysis, 17th ed. Association of Official Analytical Chemists: Gaithersburg, MA, USA. 2000.

20. Bandara NM, Batista I, Nunes ML, Empis JM. Seasonal variation in the chemical composition of horse-mackerel (Trachurus trachurus). Eur Food Res Technol. 2001;212:535–9.

21. Ratledge C. Fatty acid biosynthesis in microorganisms being used for single cell oil production. Biochimie. 2004;86:807–15.

22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.

23. Covaci A, Voorspoels S, Thomsen C, van Bavel B, Neels H. Evaluation of total lipids using enzymatic methods for the normalization of persistent organic pollutant levels in serum. Sci Total Environ. 2006:361–6.

24. Bligh E, Dyer W. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911–7.

25. Bandara NM, Batista I, Nunes ML, Empis JM, Christie WW. Seasonal changes in lipid composition of sardine Sardinia pilchardus. J Food Sci. 1997;62:40–3.

26. Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature. 1977;266:730–2.

27. Crispim Junior CF, Pederiva CN, Bose RC, Garcia VA, Lino-de-Oliveira C, Marino-Neto J. EUTHWATCHER: validation of a tool for behavioral and video-tracking analysis in laboratory animals. Comp Biol Med. 2012;42:257–64.

28. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Spelman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:RESEARCH0034.

29. Andersen CL, Jensen JL, Omtøft T. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 2004;64:2495–500.

30. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(–ΔΔCT) method. Methods. 2001;25:402–8.

31. Fleige S, Pfaffl MW. RNA integrity and the effect on the real-time qRT-PCR performance. Mol Asp Med. 2006;27:126–39.

32. Werman MJ, Sukenik A, Mokady S. Effects of the marine unicellular alga

33. Geng T, Hu W, Broadwater MH, Snider JM, Bielawski J, Russo SB, Schwacke

34. Ramsden CE, Zamora D, Majchrzak-Hong S, Faurot KR, Broste SK, Frantz RP, 

35. Bennett DA, Morris MC. Plasma and brain fatty acid profiles in mild to moderate depression and association with long-term dementia risk. Am J Clin Nutr. 2009;90:170–6.

36. Guesnet P, Alessandri J-M. Docosahexaenoic acid (DHA) metabolism and neurotransmission. Prostaglandins Other Lipid Mediat. 2001;63:109–13.

37. Krimsky MR, Zhang Y, Li D, Chen J, Proctor B, Li Z, Wang G. Effects of dietary docosahexaenoic acid and its conversion to eicosapentaenoic acid on the omega-3 index, an emerging cardiovascular risk marker. Lipids. 2008;43:800–11.

38. Serhan CN, Petasis NA. Resolvins and protectins in inflammation-resolution. Prostaglandins Other Lipid Mediat. 2001;63:109–13.

39. Bradbury J. Docosahexaenoic acid (DHA): an ancient nutrient for the modern human brain. Nutrients. 2011;3:529–54.

40. Bandara NM, Lopes PA, Martins SV, Ferreira J, Afifia CM, Rolo EO, Correia JJ, Pinto RM, Ramos-Bueno RP, Batista I, Prates JA, Guil-Guerrero JL. Docosahexaenoic acid at the sn-2 position of structured triacylglycerols improved n-3 polyunsaturated fatty acid assimilation in tissues of hamsters. Nutr Res. 2016;36:452–63.

41. Lee KT, Akoh CC, Dawe DL. Effects of structured lipid containing omega 3 and medium chain fatty acids on serum lipids and immunological variables in mice. J Food Biochem. 1999;23:197–208.

42. Rapoport SI, Rao JS, Igarashi M. Brain metabolism of nutritionally essential polyunsaturated fatty acids depends on both the diet and the liver. Prostaglandins Leukot Essent Fatty Acids. 2007;77:251–61.

43. Barceló-Coblijn G, Murphy EJ. Alpha-linolenic acid and its conversion to longer chain n-3 fatty acids: benefits for human health and a role in maintaining tissue n-3 fatty acid levels. Prog Lipid Res. 2009;48:355–74.

44. Domenichelli AF, Kitson AP, Chen CT, Trépanier MO, Stavro PM, Bazinet RP. The effect of docosahexaenoic acid on the whole body synthesis rates of polyunsaturated fatty acids from o-linolenic acid and linoleic acid in free-living rats. J Nutr Biochem. 2016;30:167–76.

45. Lee KT, Akoh CC, Dawe DL. Effects of structured lipid containing omega 3 fatty acids: benefits for human health and a role in maintaining tissue n-3 fatty acid levels. Prog Lipid Res. 2009;48:355–74.

46. Domenichelli AF, Kitson AP, Chen CT, Trépanier MO, Stavro PM, Bazinet RP. Effect of dietary docosahexaenoic acid (DHA) incorporation into the brain from plasma, as an in vivo biomarker of brain DHA metabolism and neurotransmission. Prostaglandins Other Lipid Mediat. 2011;96:109–13.

47. Harris WS, Lemke SL, Hansen SN, Goldstein DA, DiRienzo MA, Su H, Nemeth MA, Taylor ML, Ahmed G, George C. Stearidonic acid-enriched soybean oil increased the omega-3 index, an emerging cardiovascular risk marker. Lipids. 2008:43:800–11.

48. Domenichelli AF, Kitson AP, Chen CT, Trépanier MO, Bazinet RP. Effect of dietary docosahexaenoic acid (DHA) in vivo. J Nutr Biochem. 2016;33:91–102.

49. Kitson AP, Metherel AH, Chen CT, Domenichelli AF, Trépanier MO, Berger A, Bazinet RP. Effect of dietary docosahexaenoic acid (DHA) on brain phospholipids in aging and in Alzheimer’s disease. Lipids. 1991;26:421–5.

50. Eshel T, Chen CT, Metherel AH, Chen CT, Domenichelli AF, Trépanier MO, Bazinet RP, Berger A, Bazinet RP. Effect of dietary docosahexaenoic acid (DHA) on brain phospholipids in aging and in Alzheimer’s disease. Lipids. 1991;26:421–5.

51. Park Y, Moon HJ, Kim SH. Docosahexaenoic and eicosapentaenoic acids: effects on cognitive function and platelet aggregation in healthy human volunteers. J Nutr Biochem. 2006;17:297–303.

52. Soderberg M, Edlund C, Kristensson K, Dallner G. Fatty acid composition of brain phospholipids in aging and in Alzheimer’s disease. Lipids. 1991;26:421–5.

53. Eskelinen MH, Nganud T, Hekalaa EL, Tuomilehto J, Nissinen A, Soininhein H, Kivipelto M. Fat intake at midlife and cognitive impairment later in life: a population-based CAIDE study. Int J Geriatr Psychiatry. 2008;23:741–7.

54. Devere OE, Grodstein F, van Rooij FJ, Hofman A, Rosner B, Stampfer MJ, Witterman JC, Breitler MM. Dietary intake of fish and omega-3 fatty acids in relation to long-term dementia risk. Am J Clin Nutr. 2009;90:170–6.

55. Cunanne SC, Schneider JA, Tangney C, Tremblay-Mercier J, Fortier M, Bennett DA, Morris MC. Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer’s disease. J Alzheimers Dis. 2012;29:691–7.

56. Guesnet P, Alessandri JM. Docosahexaenoic acid (DHA) and the developing central nervous system (CNS) – implications for dietary recommendations. Biochimie. 2011;93:7–12.

57. Park Y, Moon HJ, Kim SH. n-3 polyunsaturated fatty acid consumption produces neurobiological effects associated with prevention of depression in rats after the forced swimming test. J Nutr Biochem. 2012;23:924–8.

58. Mozaffarian D, Wu JH. (–) fatty acids and cardiovascular health: are effects of EPA and DHA shared or complementary? J Nutr. 2012;142:614S–5.

59. Gies GE, Mahoney CR, Uyey HL, Brunrey TT, Taylor HA, Kanae KB. Omega-3 fatty acids and stress-induced changes to mood and cognition in healthy individuals. Pharmacol Biochem Behav. 2015;132:10–9.

60. Heinrichs SC. Dietary omega-3 fatty acid supplementation for optimizing neuronal structure and function. Mol Nutr Food Res. 2010;54:447–56.
65. Pusceddu MM, Kelly P, Stanton C, Cryan JF, Dinan TG. n-3 polyunsaturated fatty acids through the lifespan: implication for psychopathology. Int J Neuropsychopharmacol. 2016;19:pii: pyw078.
66. Husted KS, Bouzinova EV. The importance of n-6/n-3 fatty acids ratio in the major depressive disorder. Medicina. 2016;52:139–47.
67. Morgese MG, Trabace L. Maternal malnutrition in the etiopathogenesis of psychiatric diseases: role of polyunsaturated fatty acids. Brain Sci. 2016;6:pii: E24.
68. Levant B, Ozias MK, Davis PF, Winter M, Russell KL, Carlson SE, Reed GA, McCaslon KE. Decreased brain docosahexaenoic acid content produces neurobiological effects associated with depression: interactions with reproductive status in female rats. Psychoneuroendocrinol. 2008;33:1279–92.
69. Wu A, Ying Z, Gomez-Pinilla F. Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. J Neurotrauma. 2004;21:1457–67.
70. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr. 2000;71:343S–8S.
71. Simopoulos AP. An increase in the omega-6/omega-3 fatty acid ratio increases the risk for obesity. Nutrients. 2016;8:128.
72. Tao X, Finkbeiner S, Arnold DB, Shaywitz AJ, Greenberg ME. Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron. 1998;20:709–26.
73. Aid T, Kazantseva A, Piirsoo M, Palm K, Timmusk T. Mouse and rat BDNF gene structure and expression revisited. J Neurosci Res. 2007;85:525–35.